Bavarian Nordic Moves to Expand Mpox Vaccine Use to Children

Bavarian Nordic Moves to Expand Mpox Vaccine Use to Children

By, Admin 30 March 2026

Bavarian Nordic has taken a significant regulatory step by submitting clinical data to the European Medicines Agency (EMA) to extend the use of its MVA-BN vaccine to children aged 2 to 11 years.

If approved, this could mark a major expansion in protection against Mpox and smallpox—especially for one of the most vulnerable populations.

What’s Driving the Submission?

The filing is backed by Phase 2 clinical data comparing children and adults:

  • 227 children (2–11 years)
  • 224 adults

Key Findings

  • Non-inferior immune response in children vs adults
  • Comparable safety profile across both groups
  • Standard two-dose regimen used

The study was conducted in:

  • Democratic Republic of Congo
  • Uganda

These regions have seen active mpox outbreaks, affecting both adults and children.

Why This Matters: Children Are at Higher Risk?

While global mpox risk has moderated, children remain disproportionately affected.

Key Concerns

  • Higher risk of severe disease
  • Increased vulnerability due to:
    • Malnutrition
    • Malaria
    • HIV

According to Coalition for Epidemic Preparedness Innovations (CEPI), expanding vaccine access is critical to:

  • Reduce disease severity
  • Limit ongoing transmission
  • Protect high-risk pediatric populations

Regulatory Timeline: What Happens Next?

If the EMA review is successful:

  • The Marketing Authorisation could be extended
  • Vaccine use may include children from 2 years of age
  • Decision expected later in 2026

This could also influence other global regulators to follow suit.

The Vaccine: MVA-BN Explained

The MVA-BN (Modified Vaccinia Ankara – Bavarian Nordic) vaccine is currently:

  • The only non-replicating mpox vaccine widely approved globally
  • Marketed under different names:
    • Jynneos (U.S.)
    • Imvamune (Canada)
    • Imvanex (EU/UK)

What Makes It Different?

  • Non-replicating virus platform → safer for immunocompromised individuals
  • Originally developed as a smallpox vaccine
  • Currently approved for individuals aged 12 and above at risk

Ground-Level Insight from Africa

Clinical investigators highlighted the urgency of pediatric protection. In countries like the Democratic Republic of Congo:

  • Children under 12 represent ~30% of the population
  • They face higher complication rates
  • Close contact environments increase transmission risk

Expanding vaccination could:

  • Strengthen outbreak control
  • Reduce healthcare burden
  • Lower economic impact of recurring outbreaks

Strategic Angle: More Than Just an Approval

For Bavarian Nordic, this move signals:

  • Expansion into broader population segments
  • Strengthening position as a global vaccine supplier
  • Alignment with public health preparedness goals

The company already serves as a key supplier of mpox and smallpox vaccines to governments worldwide.

Final Take

This isn’t just a label expansion, it’s a strategic shift toward inclusive immunization.

If approved, it will:

  • Close a major gap in pediatric protection
  • Support outbreak containment in high-risk regions
  • Reinforce the global push toward equitable vaccine access

The next milestone to watch: EMA’s decision—and whether other regulators quickly follow.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!